medigraphic.com
ISSN 1665-3254 (Print)
Revista Oficial de la Universidad Biomédica Rafael Guízar y Valencia A. C.

2006, Number 2

<< Back Next >>

Plasticidad y Restauración Neurológica 2006; 5 (2)

Early lesions in Alzheimer’s diseases

Troncoso JC, Kawas CH, Pardo CA, Aguilar RF

Language: Spanish
References: 37
Page: 129-135
PDF size: 354.66 Kb.


ABSTRACT

This paper report on the neuropathological examinations studies of a 74 year-old woman with illness of Alzheimer’s (AD) and of her 47 year-old non-demented daughter. The mother’s brain showed fully developed pathological changes of AD. By constrast, the brain of daughter’s revealed only perineural depositions of diffuse amyloid in cerebral cortex and striking abnormalities of the endosomal-lisosomal system, without neurofibrilary, glial, or microglial changes. These observations suggest that the amyloid depositions and the endosomal-lisosomal changes are early events in the late onset AD and that they may precede the onset of dementia by several decades. These findigns give a newly information about diagnostic value in terms of physiopathology.


REFERENCES

  1. Chartier-Harlin MC, Crawford F, Houlden H, et al. Early-onset Alzheimer’s disease caused by mutations at codon 717 of the b-amyloid precursor protein gene. Nature 1991;353:844-846.

  2. Goate A, Chartier-Harlin MC, Mullan M, Brown J, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991;349:704-6.

  3. Naruse S, Igarashi S, Kobayashi H, et al. Mis-sense mutation Val->Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer’s disease. Lancet 1991;337:978-9.

  4. Hendricks L, van Duijn CM, Cras P, et al. Presenile dementia and cerebral hemorrhage linked to a mutation at codon 692 of the b-amyloid precursor protein gene. Nature Genetics 1992;1:218-21.

  5. Mullan M, Crawford F, Axelman K, Houlden, Lillius L, Winblad B, Lannfelt L. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of b-amyloid. Nature Genetics 1992;1:345-7.

  6. Corder EH, Saunders, Strittmatter WJ, et al. Gene dose of apolipoprotein-E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921-3.

  7. St George-Hyslop PH, Haines P, Rogaev E, et al. Genetic evidence for a novel familial Alzheimer’s disease locus on chromosome 14. Nature Genetics 1992;2:330-4.

  8. Alzheimer’s Disease Collaborative Group. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nature Genetics 1995;11:219-22.

  9. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995;375:754-60.

  10. Wasco W, Pettingell WP, Jondro PD, et al. Familial Alzheimer’s chromosome 14 mutations. Nature Med 1995;1:848.

  11. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 1995;269:973-7.

  12. Levy-Lahad E, Wijsman EM, Nemens E, et al. A familial Alzheimer’s disease locus on chromosome 1. Science 1995;269:970-3.

  13. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 1995;376:775-8.

  14. Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: b-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 1994;53:429-37.

  15. Blacker D, Wilcox MA, Laird NM, et al. Alpha-2-macroglobulin is associated with Alzheimer’s disease. Nature Genetics vol. 1998. (In Press)

  16. Kang DE, Saitoh T, Chen X, et al. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer’s disease. Neurology 1997;49:56-61.

  17. Von Koch CS, Roskams AJ, Ronnett GV, et al. Analysis of mice with targeted APLP2 and APLP2/APP alleles. Soc Neurosci Abstr 1995;21:259. (Abstract).

  18. Alzheimer A, Perusini G. Alzheimer’s first case rediscovered. Padova: Liviana Press, 1989.

  19. Mirra SS, Heyman A, McKeel D, et. al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991;41:479-86.

  20. a.R.I.W.G.o.D.C.f.t.N.A.o.A.d. The National Institute on Aging, Consensus recommendations for the post mortem diagnosis of Alzheimer’s disease. Neurobiol Aging 1997;18:S1-S2.

  21. Markesbery WR. The diagnosis of Alzheimer’s disease. Arch Pathol Lab Med 1993;117:129-31.

  22. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 1990;27:457-63.

  23. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-80.

  24. McIntosh LJ, Trush MA, Troncoso JC. Increased susceptibility of Alzheimer’s disease temporal cortex to oxygen free radical-mediated processes. Free Radic Biol Med 1997;23:183-90.

  25. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989;107:341-6.

  26. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol (Berl) 1982;57:239-42.

  27. Rogers J, Cooper NR, Webster S, et al. Complement activation by b-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992;89:10016-20.

  28. Pasinetti GM. Inflammatory mechanisms in neurodegeneration and Alzheimer’s disease: The role of the complement system. Neurobiol Aging 1996;17:707-16.

  29. Morris JC, McKeel DW Jr., Storandt M, et al. Very mild Alzheimer’s disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology 1991;41:469-78.

  30. Troncoso JC, Martin LJ, Dal Forno G, Kawas CH. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging 1996;17:365-71.

  31. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-8.

  32. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC. Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology 1994;44:227-32.

  33. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997;48:626-32.

  34. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993;43:1609-11.

  35. Troncoso JC, Cataldo AM, Nixon RA, et al. Neuropathology of preclinical and clinical late-onset familial Alzheimer’s disease. Ann Neurol 1998;43:673-6.

  36. Burger PC, Vogel FS. The development of the pathologic changes of Alzheimer’s disease and senile dementia in patients with Down’s syndrome. Am J Pathol 1973;73:457-76.

  37. Cork LC. Neuropathology of Down syndrome and Alzheimer disease. Am J Med Genet 1990;7Suppl:282-6.




2020     |     www.medigraphic.com